ARS Pharmaceuticals, Inc.
SPRYHealthcare|Biotechnology|US
$2.79
+0.14 (+5.28%)
Cash / Share
$1.39
About
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Stock Price
-66.0%(1Y)
1M
-38.8%
3M
-54.7%
6M
-68.1%
YTD
-76.1%
1Y
-68.6%
3Y
-22.1%
5Y
-68.3%
Pipeline Summary
20 total trials1
Phase 1
3
Phase 2
1
Phase 3
2
Phase 4
Completed: 7Recruiting: 5Unknown: 4Not Yet Recruiting: 3Terminated: 1
Active Trials (5)
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
NCT06834165Allergic Reactions
Phase 4Recruiting
Enrollment: 600 participants
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
NCT06927999Urticaria Chronic
Phase 2Recruiting
Enrollment: 42 participants
Real-world Effectiveness, Safety & Immunogenicity of Chikungunya Vaccination: Ambispective Study in Reunion & French Guiana
NCT06928753Chikungunya Virus Infection
Phase 4Recruiting
Enrollment: 1,505 participants
Screening for Cancers in the Oral CAvity
NCT01958762Oral Cavity Cancer
N/ARecruiting
Enrollment: 100 participants
Evaluation of a New Communication Aid Tool to Favor Global Patient Centered Care
NCT04179695Parkinson's Disease
N/ARecruiting
Enrollment: 120 participants
Key Facts
Market Cap$277.5M
Employees158 (+2% YoY)
CEODonn Casale
IPO DateDec 4, 2020
Beta0.88
52-Week Range$2.44 – $13.15
Avg Volume1,876,454
ExchangeNASDAQ
Websitears-pharma.com
Ownership
Float65.6%
Shares Outstanding99.4M
Recent Insider Trades
Slebir John LAWARD
Nov 2, 20261,199,482 shares @ $3.05
Slebir John LOTHER
Oct 26, 20260 shares
Casale DonnAWARD
Oct 1, 20261,036,923 shares @ $4.12
Smith Margaret EkinsAWARD
Sep 1, 20261,001,738 shares @ $5.77
Smith Margaret EkinsOTHER
Aug 17, 20260 shares
Peers
Recent News
ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
Nov 6, 2026 · benzinga.com
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript
Nov 6, 2026 · seekingalpha.com
ARS Pharmaceuticals Q3 Earnings Call Highlights
Nov 5, 2026 · marketbeat.com
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
Nov 5, 2026 · zacks.com
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
Nov 3, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:35 AM